Homology Medicines, Inc.

NasdaqGS:FIXX Stok Raporu

Piyasa değeri: US$54.3m

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Homology Medicines Gelecekteki Büyüme

Future kriter kontrolleri 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Homology Medicines.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Biotechs kazanç büyümesi28.6%
Gelir büyüme oranın/a
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme25 Mar 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Homology Medicines (NASDAQ:FIXX) Will Have To Spend Its Cash Wisely

Nov 16
Homology Medicines (NASDAQ:FIXX) Will Have To Spend Its Cash Wisely

Homology Medicines appoints new CEO, chairperson

Sep 06

Homology announces peer-reviewed preclinical data publication on its AAVHSC16 capsid

Jul 05

Here's Why We're Watching Homology Medicines' (NASDAQ:FIXX) Cash Burn Situation

Jan 28
Here's Why We're Watching Homology Medicines' (NASDAQ:FIXX) Cash Burn Situation

Homology Medicines: In Vivo Gene Therapy Platform With Delayed Lead Trial Coming Back Online

Oct 22

We Think Homology Medicines (NASDAQ:FIXX) Can Afford To Drive Business Growth

Sep 18
We Think Homology Medicines (NASDAQ:FIXX) Can Afford To Drive Business Growth

Growth Investors: Industry Analysts Just Upgraded Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts By 20%

Aug 14
Growth Investors: Industry Analysts Just Upgraded Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts By 20%

Industry Analysts Just Made A Sizeable Upgrade To Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts

May 22
Industry Analysts Just Made A Sizeable Upgrade To Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts

Homology Medicines (FIXX) Investor Presentation - Slideshow

May 05

Homology Medicines (NASDAQ:FIXX) Is In A Good Position To Deliver On Growth Plans

Apr 17
Homology Medicines (NASDAQ:FIXX) Is In A Good Position To Deliver On Growth Plans

Are Institutions Heavily Invested In Homology Medicines, Inc.'s (NASDAQ:FIXX) Shares?

Mar 13
Are Institutions Heavily Invested In Homology Medicines, Inc.'s (NASDAQ:FIXX) Shares?

Homology Medicines' (NASDAQ:FIXX) Stock Price Has Reduced 25% In The Past Year

Feb 03
Homology Medicines' (NASDAQ:FIXX) Stock Price Has Reduced 25% In The Past Year

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:FIXX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/2024N/A-40N/AN/A1
12/31/20231-113-96-96N/A
9/30/20232-131-102-102N/A
6/30/20233-132-102-102N/A
3/31/20233-126-109-109N/A
12/31/20223-5-115-114N/A
9/30/20223-4-119-117N/A
6/30/20224-1-119-117N/A
3/31/20225-3-113-111N/A
12/31/202134-96-112-110N/A
9/30/202134-92-94-91N/A
6/30/202133-90-97-94N/A
3/31/202131-94-101-98N/A
12/31/20203-129-98-94N/A
9/30/20202-123-116-109N/A
6/30/20202-124-114-106N/A
3/31/20202-115-113-99N/A
12/31/20192-104-113-91N/A
9/30/20192-99-107-73N/A
6/30/20193-83-98-61N/A
3/31/20194-69-84-49N/A
12/31/20185-56-68-43N/A
9/30/20184-49-22-12N/A
6/30/20183-41-9-4N/A
3/31/20181-35-20N/A
12/31/2017N/A-3056N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if FIXX's forecast earnings growth is above the savings rate (2.3%).

Kazançlar ve Piyasa: Insufficient data to determine if FIXX's earnings are forecast to grow faster than the US market

Yüksek Büyüme Kazançları: Insufficient data to determine if FIXX's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if FIXX's revenue is forecast to grow faster than the US market.

Yüksek Büyüme Geliri: FIXX is forecast to have no revenue next year.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if FIXX's Return on Equity is forecast to be high in 3 years time


Büyüyen şirketleri keşfedin